Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer’s disease
ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) — Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease. Neurimmune licensed its antibody aducanumab for the treatment and prevention of Alzheimer’s disease to Biogen in … Read more